Last quarter (Q2 2022), Celadon Pharmaceuticals PLC's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, Celadon Pharmaceuticals PLC's net income was $―. See Celadon Pharmaceuticals PLC’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Aug 20	Aug 19
Total Revenue	-	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	$ 0.00	$ 54.78K	$ 51.98K
Gross Profit	-	-	$ 0.00	$ -54.78K	$ -51.98K
Operating Expense	-	$ 722.38K	$ 720.65K	$ 85.38K	$ 75.73K
Operating Income	-	$ -722.38K	$ -720.65K	$ -140.16K	$ -127.71K
Net Non Operating Interest Income Expense	-	$ 2.02K	$ -339.15K	$ 12.04K	$ 14.56K
Other Income Expense	-	-	-	-	-
Pretax Income	-	$ -720.37K	$ -1.06M	$ -174.51K	$ -191.32K
Tax Provision	-	-	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-
Net Income Common Stockholders	-	$ -720.37K	$ -1.06M	$ -174.51K	$ -191.32K
Basic EPS	-	$ -0.10	$ -0.02	$ -0.03	$ -0.04
Diluted EPS	-	$ -0.10	$ -0.02	$ -0.03	$ -0.04
Basic Average Shares	-	$ 7.50M	$ 61.67M	$ 6.13M	$ 5.31M
Diluted Average Shares	-	$ 7.50M	$ 61.67M	$ 6.13M	$ 5.31M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	$ 87.58K	-	-
Total Expenses	-	-	$ 720.65K	$ 140.16K	$ 127.71K
Net Income From Continuing And Discontinued Operation	-	$ -720.37K	$ -1.06M	$ -174.51K	$ -191.32K
Normalized Income	-	$ -583.50K	$ -1.06M	$ -128.12K	$ -113.15K
Interest Expense	-	-	$ 339.15K	-	-
EBIT	-	$ -720.37K	$ -720.64K	$ -140.16K	$ -127.71K
EBITDA	-	$ -720.37K	$ -559.79K	$ -140.16K	$ -127.71K

Currency in USD

Celadon Pharmaceuticals PLC Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing